| Assessment Status |
NCPE assessment ongoing |
| HTA ID |
21007 |
| Drug |
Cemiplimab |
| Brand |
Libtayo® |
| Indication |
Is indicated as monotherapy for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (mCSCC or laCSCC) who are not candidates for curative surgery or curative radiation. |
| Rapid review commissioned |
15/03/2021 |
| Rapid review completed |
23/03/2021 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of cemiplimab (Libtayo®) compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE |
31/03/2021 |
| Pre-submission consultation with Applicant |
29/11/2021 |
| Full submission received from Applicant |
23/01/2023 |
| Preliminary review sent to Applicant |
08/06/2023 |
| NCPE assessment re-commenced |
26/07/2023 |
